anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
In this study, epiduroscopic discectomy procedures performed between January 2012 and July 2016 at the Algology Clinic of the Department of Anesthesiology and Reanimation, Sakarya University Training and Research Hospital, were examined retrospectively. After approval was received from the Sakarya University Faculty of Medicine's Ethics Committee, patient information was obtained from the KarMed (Kardelen Software, Turkey) hospital information system. Files were scanned from the hospital archive. The age, gender, weight, lumbar disc herniation level, preoperative and postoperative surgical history, amount of physiological saline used during the procedure and duration of the procedure, whether a lumbar epidural steroid (LES) was used during the procedure, the amount of epiduroscopic laser use during the procedure, and complications after the procedure were examined. The Oswestry Disability Index (ODI) and Visual Analogue Scale (VAS) scores were recorded preoperatively, as well as after 2 weeks and 2, 6, and 12 months postoperatively from the patient files.

The 2007 Number Cruncher Statistical System (NCSS, Kaysville, Utah, USA) program was used for statistical analysis. The Student t-test and Mann-Whitney U test were used for descriptive statistical methods (mean, standard deviation, median, frequency, ratio, minimum, maximum) in two groups, as well as the normal distribution of quantitative data. The Kruskal-Wallis test and Mann-Whitney U test were used in the comparison of three groups with no normal distribution. The Pearson Chi-square test was used to evaluate qualitative data, and Spearman's correlation analysis was used to evaluate intervariable relationships. The Friedman and Wilcoxon signed ranks tests were used in the evaluation of three or more follow-up parameters without normal distribution. Diagnostic screening tests (sensitivity, specificity) and receiver operating characteristic (ROC) analysis were used to determine the cutoff value for age. Significance was evaluated at the level of p \< (0.01).
Spironolactone and hydrochlorothiazide tablets are a combination of two diuretic agents with different but complementary mechanisms and sites of action, thereby providing additive diuretic and antihypertensive effects. Additionally, the spironolactone component helps to minimize the potassium loss characteristically induced by the thiazide component.

The diuretic effect of spironolactone is mediated through its action as a specific pharmacologic antagonist of aldosterone, primarily by competitive binding of receptors at the aldosterone-dependent sodium-potassium exchange site in the distal convoluted renal tubule. Hydrochlorothiazide promotes the excretion of sodium and water primarily by inhibiting their reabsorption in the cortical diluting segment of the distal renal tubule.

Spironolactone and hydrochlorothiazide is effective in significantly lowering the systolic and diastolic blood pressure in many patients with essential hypertension, even when aldosterone secretion is within normal limits.

Both spironolactone and hydrochlorothiazide reduce exchangeable sodium, plasma volume, body weight, and blood pressure. The diuretic and antihypertensive effects of the individual components are potentiated when spironolactone and hydrochlorothiazide are given concurrently.
PURPOSE:To avoid formation of substances having different configurations and obtain the subject antibiotic substance in good yield and high purity by using a specific butynyl acylate as a starting substance, enzymically hydrolyzing the aforementioned substance, protecting OH group and epoxidizing, etc., the resultant compound. CONSTITUTION:A compound expressed by formula I (R1 is lower acyl) is enzymically hydrolyzed to provide a compound expressed by formula II. The OH group thereof is then protected with a group (A) (A is tert. butyldiphenylsilyl) and subsequently epoxidized to afford a compound expressed by formula III, which is then hydrolyzed, further reacted with 6,6-ethyenedioxy-4- methylheptylaryl sulfone in the presence of an alkyl metal and then subjected to removal of the aryl sulfone. Conversion into acetonide and deacetalization are carried out and the resultant compound is subsequently reacted with an alkyl dialkylphosphono-3-methyl-2-butenoate to perform desilylation and oxidation. Furthermore, removal of the acetonide is carried out to protect the primary OH group and the obtained compound is hydrolyzed and lactonized. The protecting group is then removed to provide the objective compound expressed by formula IV.
The present invention relates to a system for selecting and delivering health functional food matching a body function of a customer in a customized manner. A customer signs up for a membership on a homepage of health functional food and then consults a nurse who is a manager of a health functional food company. Then the customer personally transmits body composition measurement analysis data obtained by measuring a body function of the customer by a delivered body composition measurement analysis device to a management server and a database of the health functional food company via a wired/wireless device. Health food data stored in the database and health food prescription information of the corresponding customer in connection with effect information data of the health food are generated based on the body composition measurement analysis data of the customer for analysis and evaluation of integrated health information of the customer based on the body composition measurement analysis data of the customer by the management server. The nurse who is a manager of the health functional food company and the customer consult via a network or wired/wireless communication based on the health food data and the prescription information. Then health functional food matching the body function of the customer is delivered to systematically and scientifically prescribe health functional food based on the body composition measurement analysis data of the customer to promote the health of the customer and prevent diseases.
The invention belongs to the technical field of medical materials, and discloses a method for activating an anti-tumor compound by bioorthogonal photocatalytic oxidative dehydrogenation, a composition and application. The method comprises the following steps: the dihydrobenzophenanthridine alkaloid is subjected to dehydrogenation reaction under the conditions of illumination and oxygen and under the action of a photocatalyst to obtain the benzophenanthridine alkaloid. The composition comprises dihydrobenzophenanthridine alkaloid and a photocatalyst. The composition is applied to the preparation of a cell nucleus targeting light-activated imaging agent and/or a light-activated anti-tumor product. The oxidative dehydrogenation method is simple and efficient; the dihydrobenzophenanthridine alkaloid and the photocatalyst have high photo-activation efficiency under the aerobic condition; the fluorescent material is used in cells and is illuminated under the condition of oxygen, the specific light-activated fluorescence imaging of cell nucleus targeting in living cells can be realized, and the fluorescent material has the advantages of high light-activated efficiency, low cytotoxicity and the like. Through illumination control, the composition has a good anti-tumor effect.
BACKGROUND: Cardiac surgery-associated acute kidney injury (CSA-AKI) is associated with high short- and long-term mortality rates. The prediction of CSA-AKI is crucial for early detection and treatment. Current predictive models may be improved by potentially useful preoperative and intraoperative information.
METHODS: This multicenter prospective cohort study recruited 261 consecutive patients at high risk for developing CSA-AKI, based on a Cleveland Clinical Score (CCS) of ≥4 points from July to December 2017 in 14 hospitals in Spain and the UK. Postoperative AKI occurred in 145 (55.5%) patients. The receiver operating characteristics curve (AUC) of a base model including only the CCS was compared with models including additional preoperative and intraoperative variables such as the estimated glomerular filtration rate (eGFR) instead of plasmatic creatinine, intraoperative urine output, baseline hemoglobin, nadir hemoglobin, and glycosylated hemoglobin (HbA<inf>1c</inf>) instead of diabetes mellitus. The performance of each model for AKI was compared.
RESULTS: The CCS alone gave an AUC of 0.67 (95% CI, 0.56-0.78) for postoperative AKI. None of the single variables added to the base model CCS improve discrimination. The AUC for postoperative AKI was improved when baseline hemoglobin, eGFR instead of plasmatic creatinine, HbA<inf>1c</inf>, and nadir hemoglobin were added to the CCS (AUC=0.77; 95% CI, 0.67-0.87; P=0.02).
CONCLUSIONS: The addition of baseline hemoglobin, eGFR, HbA<inf>1c</inf>, and nadir intraoperative hemoglobin may be useful for improving the discrimination of the clinical predictive risk scores for AKI.
Patients will receive a single sham puncture into the affected knee. Sham punctures will be identical to the treatment injections in all other respects, including duration, use of sterile drapes, sterile preparation, and dimming of the lights. This procedure will include a 22g needle stick through the skin without violating the joint capsule or performing arthrocentesis.
The primary objective is the per-patient detection rate of 18F-DCFPyL in comparison with 18F-Fluorocholine. Secondary objectives include the assessment of the impact on patient treatment management, the per-region detection rate, the sensitivity and specificity on a per-patient and per-region basis, the concordance rate between both tracers, and the safety. The study was initiated in July 2020, and the recruitment of the planned 217 patients has been completed in October 2020. The follow-up phase is ongoing. Typically, as part of the routine care practice, these patients receive appropriate treatment and follow-up. The investigating sites are therefore requested for the period of 7 months after the second tracer injection, to provide any results of subsequent biopsies, imaging studies, clinical findings, PSA measurements, and disease management, if performed in routine practice. Treatment decisions are locally made at the discretion of the referring physician based on all available clinical information, including the non-masked local reports of both PET/CT and any other imaging results. After completion of the study, a consensus will be obtained from a multidisciplinary independent board (truth panel), based on the surrogate standard of reference which will include all the above-mentioned available results. Assessments will be made on a per-region and per-patient basis. The truth panel will consist in 3 independent experts not otherwise involved in the trial. All above information will be sequentially presented to the truth panel experts. The order of presentation of 18F-FCH PET/CT and 18F-DCFPyl PET/CT results will be randomized. The truth panel will have to assess the impact of each PET/CT examination on disease restaging and change in treatment intent, by filling in a patient management questionnaire after review of each PET/CT examination report.
The high rate of early recurrence in hepatocellular carcinoma (HCC) post curative surgical intervention poses a substantial clinical hurdle, impacting patient outcomes and complicating postoperative management. The advent of machine learning provides a unique opportunity to harness vast datasets, identifying subtle patterns and factors that elude conventional prognostic methods. Machine learning models, equipped with the ability to analyse intricate relationships within datasets, have shown promise in predicting outcomes in various medical disciplines. In the context of HCC, the application of machine learning to predict early recurrence holds potential for personalized postoperative care strategies. This editorial comments on the study carried out exploring the merits and efficacy of random survival forests (RSF) in identifying significant risk factors for recurrence, stratifying patients at low and high risk of HCC recurrence and comparing this to traditional COX proportional hazard models (CPH). In doing so, the study demonstrated that the RSF models are superior to traditional CPH models in predicting recurrence of HCC and represent a giant leap towards precision medicine.
Mitral annular disjunction (MAD), a separation between the left atrium/mitral valve annulus and the left ventricular myocardium, is frequently seen in patients with arrhythmic mitral valve prolapse. Although an association exists between MAD and ventricular arrhythmias, little is known regarding the identification of individuals at high risk. Multimodality imaging including echocardiography, computed tomography, cardiac magnetic resonance, and positron emission tomography can play an important role in both the diagnosis and risk stratification of MAD. Due to a paucity of data, clinical decision making in a patient with MAD is challenging and remains largely empirical. Although MAD itself can be corrected surgically, the prevention and treatment of associated arrhythmias may require medical therapy, catheter ablation, and an implantable cardioverter-defibrillator. Prospective data are required to define the role of implantable cardioverter-defibrillators, targeted catheter ablation, and surgical correction in selected, at-risk patients.
Escitalopram has been approved by FDA in the treatment of adolescents with major depressive disorder since March 2009. Although Wagner and colleagues reported that escitalopram has a tendency toward positive findings for the treatment of pediatric patients with major depressive disorder in their study it was found that this effect has not reached a statistical significance. Noteworthy the authors reported statistical significance for escitalopram when they only included adolescent subgroup into further analysis. However, there are also clinical trials in the literature reporting the effectiveness of escitalopram on adolescence major depressive disorder (Emslie, Findling). It was indicated that no serious adverse effect of escitalopram was reported in these studies comparing escitalopram with placebo. In this study the authors aimed to investigate the effect and reliability of the drug in the treatment of adolescents with major depressive disorder and/or anxiety disorders. Additionally, cognitive behavioral therapy and SSRIs are indicated for the first-line treatment of anxiety disorders. The authors included escitalopram for the treatment of pediatric anxiety disorders.
Antipsychotics with weight gain as side effect and vitamin D receptor dysfunction associated with single nucleotide polymorphisms (VDR SNPs) may have different effects on vitamin D status. Hence, present study aimed to investigate the relationship between vitamin D with body mass index (BMI), antipsychotics and VDR SNPs (rs2228570, rs1544410, rs7975232 and rs731236) in Malaysian patients with schizophrenia. Serum vitamin D level was measured using competitive enzyme-linked immunosorbent assay kit. VDR SNPs were analyzed using polymerase chain reaction-restriction fragment length polymorphism. We found significantly lower serum vitamin D level in patients with schizophrenia (p < 0.01), especially those taking atypical antipsychotics (p = 0.02) and combined antipsychotics (p = 0.02) and obese (BMI ≥27.5 kg/m2) patients (p = 0.04) after adjustment for covariates. For VDR SNPs, the CT genotype of rs1544410, CA genotype of rs7975232, and AA and AG genotypes of rs731236 may contribute to the significant decreased serum vitamin D level in patients (p < 0.05). Nevertheless, these relationships may differ by populations or medical conditions. The hypotheses of volumetric dilution and sequestration of vitamin D may explain the lower vitamin D level in obese patients. In addition, lifestyle factors such as poor diet and lack of physical activity with less sunlight exposure may cause reduced vitamin D level among patients. As patients in present study were prescribed with various antipsychotics, the effect of each antipsychotic on vitamin D level could not be determined. Thus, future studies should investigate the effect of different types of antipsychotics and obesity on vitamin D level in schizophrenia.
OBJECTIVE: This study aims to assess the trends in the proportions of weight loss efforts among Korean adolescents aged 10-18 years from 2005 to 2021, examining variations based on weight status, to examine factors related to weight loss efforts by weight status, and to evaluate weight loss efforts based on the combination of measured and self-perceived weight status.
METHODS: Complex sample design analyses were conducted on a dataset comprising 10,760 adolescents, utilizing information from the Korea National Health and Nutrition Examination Survey, a nationally representative dataset. Participants were categorized into non-overweight and overweight groups using a BMI percentile threshold of 85.
RESULTS: 22-29 % of non-overweight adolescents and 54-77 % of adolescents with overweight engaged in weight loss efforts. Among adolescents who attempted to lose weight from 2005 to 2017, 39.5-57.1 % tried both of diet and exercise, 22.7-47.4 % tried exercise alone, and 10.2-26.7 % tried diet alone. Female gender, older age, and higher self-perceived weight status were associated with increased odds of weight loss efforts, irrespective of actual weight status. For adolescents perceiving themselves as obese, the odds of attempting weight loss were 8.32 for non-overweight boys, 2.02 for non-overweight girls, 15.28 for overweight boys, and 5.77 for overweight girls compared to controls who were non-overweight and perceived themselves as not obese.
CONCLUSION: Weight loss efforts among Korean adolescents aged 10 to 18 remained consistent irrespective of their actual weight over 16 years. Throughout this period, adolescents who perceived themselves as obese were more likely to attempt weight loss, independent of their true weight status. Hence, subjective weight perception plays a significant role in influencing weight loss behaviors among adolescents.
PURPOSE:To obtain a drug for lowering blood alcoholic level capable of lowering the blood alcoholic level after drinking in a short time and effective in preventing hangover, etc., by mixing pressed juices of respective materials of cabbage, Perilla frutescens purpurea Makino, carrot and parsley at a specific weight ratio. CONSTITUTION:Pressed juices of respective materials of cabbage, Perilla frutescens purpurea Makino, carrot and parsley are mixed at about 4:3:2:1 weight ratio of the cabbage : Perilla frutescens purpurea Makino : carrot : parsley. The pressed juices are obtained by pressing the materials in a juicer or mixer. The Perilla frutescens purpurea Makino is an edible annual herb and used for coloring pickled UME (plum), etc., has strong epidemic preventing properties with simultaneous hematocathartic action and hematopoiesis by sterilizing various germs in blood. Raw juice of the carrot has effects on impartment of vitality to the heart. The respective ingredients have no factor in causing disturbance in physical conditions by side effects thereof. The above- mentioned lowering drug is capable of returning the blood alcoholic level to the normal value within at least 120min.
The primary aim of this research was to explore the functions of Wtap and Ythdf1 in regulating neuronal Lipocalin-2 (Lcn2) through m6A modification in traumatic brain injury (TBI). By employing transcriptome sequencing and enrichment analysis, we identified the Wtap/Ythdf1-mediated Lcn2 m6A modification pathway as crucial in TBI. In our in vitro experiments using primary cortical neurons, knockout of Wtap and Ythdf1 led to the inhibition of Lcn2 m6A modification, resulting in reduced neuronal death and inflammation. Furthermore, overexpression of Lcn2 in cortical neurons induced the activation of reactive astrocytes and M1-like microglial cells, causing neuronal apoptosis. In vivo experiments confirmed the activation of reactive astrocytes and microglial cells in TBI and importantly demonstrated that Wtap knockdown improved neuroinflammation and functional impairment. These findings underscore the significance of Wtap/Ythdf1-mediated Lcn2 regulation in TBI secondary injury and suggest potential therapeutic implications for combating TBI-induced neuroinflammation and neuronal damage.
PURPOSE: An attenuated avian infectious bronchitis virus and a vaccine containing the same for avian infectious bronchitis are provided to prevent avian infectious bronchitis virus. CONSTITUTION: An attenuated avian infectious bronchitis virus strain is made by attenuating toxicity to chicken by sub-culturing virus stain and S1 protein is mutated. The mutant S1 protein is mutated from serine to tyrosine. The mutant S1 protein has an amino acid sequence of sequence number 4. The attenuated avian infectious bronchitis virus strain is IBV AVR1/08 strain(deposit number: KCTC 11467BP). A vaccine for preventing avian infectious bronchitis for preventing respiratory avian infectious bronchitis contains the attenuated avian infectious bronchitis virus strain. The vaccine additionally contains an adjuvant.
The invention discloses a seawater-cultured Wei-Shi algae strain, namely a Wei-Shi algae (Vischeria sp.) LQ-1984 strain. The strain LQ-1984 of the Weissella (Vischeria sp.), the serial number is LQ-1984, the Latin name is Vischeria sp, the collection number is CCTCC M20191120, and the strain is Vischeria sp. The mature cells have smooth surface, no cell wall protrusion, diameter of 10-15 μm, spherical or nearly spherical shape, chlorophyll in the shape of periphyton leaf and protein core. Compared with other raw materials for producing omega-7 fatty acid, the sources of the strain LQ-1984 of the Weissella (Vischeria sp.) are not limited by environment, regions, seasonality and the like, and can meet huge raw material gaps. The strain LQ-1984 of Weissella (Vischeria sp.) contains high-content omega-7 fatty acid, and the high-quality algae powder can be used for producing omega-7 related health products, foods, cosmetics and the like.
Ten patients with cerebellar ataxia will be included in our protocol. Ataxia might be due to several aetiologies, from degenerative to genetic and vascular diseases. The initial focus is vascular and spinal cerebellar ataxias. The participants will be submitted to a neuronavigation protocol for the precise location of the dentate nucleus contralateral to the most symptomatic side. After that, the participants will be randomly assigned to 5 active or 5 placebo sessions of 1Hz TMS over the located area. After the first 5 sessions and a period of at least 4 weeks washout, the participants will cross over and receive other 5 sessions, active or sham. Clinical and video evaluations will be conducted before and after active and sham cluster of sessions. The good responders, i.e., with over than 30% of improvement after the active section will be eligible to bilateral dentate nucleus DBS. After that, again, a cross-over double blind on-off stimulation will be performed. Each period (on or 0ff-stimulation) will last 4 weeks.
Application of a gel to the surface of a substrate, by simultaneously applying first and second liq. streams supplied from separate chambers of a gellable liq. and a complementary gelling agent respectively, the two streams passing along a common flow path to this surface to mix and form a gel. Pref the two streams are aq. or the gellable liq. is an aq. hydrophobic sol and the second liq is an aq. electrolyte soln. The gels may be used as thixotropic paints, cleaning agents, medical prepns, e.g. for treating burns, veterinary prods, shaving creams, cosmetics etc.